The current price of AVBP is $12.23 — it has decreased by 9.34% since the previous close. Data as of Nov 5, 2026.
AVBP is down 22.50% over the past week, down 18.95% over the past month and down 33.50% over the past year. The price is below its 200-day moving average of $26.83.
Analysts' average 12-month price target for AVBP is $25.00, which implies 104.42% upside from the current price. Individual estimates range from $18.00 to $30.00.
Of the 11 analysts covering ArriVent BioPharma, Inc., 11 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.
ArriVent BioPharma, Inc. has a market capitalization of $603.03M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, ArriVent BioPharma, Inc. posted a loss of $1.05 per share against an estimate of -$0.9873, missing expectations by 6.35%. Upcoming reports are listed in the earnings calendar.
ArriVent BioPharma, Inc. has not paid any dividends over the past year.
Companies most comparable to ArriVent BioPharma, Inc. include Exelixis, Inc., Erasca, Inc., IDEAYA Biosciences, Inc., Zai Lab Limited and HUTCHMED (China) Limited.
In the latest trading session AVBP moved between $12.19 and $13.62, a range of 11.69% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of ArriVent BioPharma, Inc. shows a strong sell rating today and a strong sell rating on the weekly timeframe. Technical ratings are indicators, not investment advice.
Over the past 52 weeks AVBP has traded between $11.36 and $35.83. The current price is 65.87% below its 52-week high.
Figures as of Nov 5, 2026. This information is provided for general purposes only and is not investment advice.